Loading...
•
Sep 30, 2022
Taysha Gene Therapies Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $26.3 million for the third quarter of 2022. They secured a $50 million strategic investment from Astellas Pharma and proceeds from a follow-on offering, extending their cash runway into the first quarter of 2024.
Astellas Pharma made a $50 million strategic investment to support the development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome.
Proceeds from follow-on offering along with Astellas strategic investment extends cash runway into first quarter of 2024
Type B end-of-Phase 2 meeting with FDA for TSHA-120 in GAN scheduled for December 13, 2022
Preliminary clinical safety and efficacy data for TSHA-102 from the first cohort of adult patients with Rett syndrome and initiation of female pediatric study expected in first half of 2023
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha Gene Therapies anticipates key milestones in 2023, including a regulatory update for TSHA-120 in GAN and preliminary clinical data for TSHA-102 in Rett syndrome.
Positive Outlook
- Regulatory update for TSHA-120 in GAN following receipt of formal meeting minutes from the Type B end-of-Phase 2 meeting with FDA expected in mid-January 2023
- Preliminary clinical safety and efficacy data for TSHA-102 from the entire first cohort of adult patients with Rett syndrome expected in H1 2023
- Initiation of Phase 1/2 trial for TSHA-102 in female pediatric patients with Rett syndrome in H1 2023